Drug Profile
Denenicokin
Alternative Names: BMS-982470; IL-21; Interleukin 21 - ZymoGenetics; rIL-21Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer National Cancer Institute (Canada); ZymoGenetics
- Class Antineoplastics; Interleukins
- Mechanism of Action Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma; Non-Hodgkin's lymphoma; Renal cancer; Solid tumours
- Discontinued Viral infections
Most Recent Events
- 01 Dec 2014 Bristol-Myers Squibb completes a phase I trial for Solid tumours in USA (NCT01629758)
- 01 Jun 2014 Bristol-Myers Squibb completes a phase I trial in Malignant melanoma (Combination therapy, Late stage disease) in USA and Puerto Rico (NCT01489059)
- 01 Jul 2012 Phase-I clinical trials in Solid tumours (late-stage disease, combination therapy) in USA (IV)